Benzinga | Apr 27, 2021 07:01AM EDT

Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis

* Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints (p<0.0001)

* Statistical Significance Achieved for Key Secondary Endpoint of Ocular Redness (p<0.0001)

* Statistical Significance Achieved for Secondary Endpoints of Ocular Tearing (p<0.0001) and Total Ocular Severity Score (p<0.0001)

* Results Consistent with Phase 3 ALLEVIATE Allergic Conjunctivitis Clinical Trial and Previous Chamber Results in Phase 2 Allergic Conjunctivitis Trial and Run-In Cohort of Phase 3 TRANQUILITY Dry Eye Disease Trial

* Reproxalap Potentially Represents the First New Allergic Conjunctivitis Therapeutic Mechanism in Decades

* Company to Discuss Results in Conference Call and Webcast at 8:00 a.m. ET Today